Jackson Colleen E, Snyder Peter J
Department of Psychology, University of Connecticut, Storrs, CT, USA.
Alzheimers Dement. 2008 Jan;4(1 Suppl 1):S137-43. doi: 10.1016/j.jalz.2007.10.008. Epub 2007 Dec 21.
Successful early detection of mild cognitive impairment (MCI) and Alzheimer's disease demands the identification of biomarkers capable of distinguishing individuals with prodromal or early cognitive impairment from healthy aging adults. Many laboratories are engaged in the discovery and validation of a wide array of potential genetic, proteomic, cognitive, and other types of biomarkers.
This review focuses on the application of quantitative electroencephalography (qEEG) and event-related potential (ERP) technologies as markers of prodromal impairment and early disease progression. It is the aim of this review to critically assess where this field currently stands, as well as future directions for EEG biomarker development.
As a neuroimaging tool that is relatively inexpensive, potentially portable, and capable of providing high-density spatial mapping, qEEG offers a noninvasive, rapid, and replicable method for assessing age-related and disease-related neurophysiologic change.
As different signature changes associated with particular stages of disease burden are identified and validated, we anticipate expanded application of qEEG as a reliable and sensitive biomarker(s) of MCI and early Alzheimer's disease.
成功早期检测轻度认知障碍（MCI）和阿尔茨海默病需要识别能够区分前驱期或早期认知障碍个体与健康老年成年人的生物标志物。许多实验室都在致力于发现和验证大量潜在的遗传、蛋白质组学、认知及其他类型的生物标志物。
本综述聚焦于定量脑电图（qEEG）和事件相关电位（ERP）技术作为前驱期损伤和疾病早期进展标志物的应用。本综述旨在批判性地评估该领域目前的状况以及脑电图生物标志物开发的未来方向。
作为一种相对廉价、可能便于携带且能够提供高密度空间映射的神经成像工具，qEEG提供了一种用于评估与年龄相关和疾病相关神经生理变化的非侵入性、快速且可重复的方法。
随着与疾病负担特定阶段相关的不同特征性变化被识别和验证，我们预计qEEG作为MCI和早期阿尔茨海默病的可靠且敏感的生物标志物将得到更广泛的应用。
